Source comparison
TB-500 Safe Side Effects: Comparison Across Research Peptides
To contextualize whether TB-500 is safe relative to side effects, comparing it to other commonly researched regenerative and recovery peptides clarifies where it sits on the risk spectrum. TB-500 Actin regulation, tissue repair, angiogenesis Headache, lethargy
This comparison does not assign a generated winner or score.
- To contextualize whether TB-500 is safe relative to side effects, comparing it to other commonly researched regenerative and recovery peptides clarifies where it sits on the risk spectrum.
- TB-500
- Actin regulation, tissue repair, angiogenesis
- Headache, lethargy, injection-site reactions
- Low. Theoretical angiogenic risk in malignancy
- Well-tolerated in research; lacks formal human safety trials but adverse event incidence is low
- BPC-157
- Gastric protective, angiogenic, VEGF modulation
- Nausea, dizziness, injection-site reactions
- Low to moderate. Angiogenic concerns similar to TB-500
- Slightly higher GI side effect incidence; otherwise comparable safety profile
- IGF-1 LR3
- Insulin-like growth signaling, muscle hypertrophy
- Hypoglycemia, joint pain, edema
- Moderate. Risk of hypoglycemia and potential mitogenic effects
- Requires careful blood glucose monitoring; higher systemic risk than TB-500
- Thymosin Alpha-1
- Immune modulation, T-cell differentiation
- Fatigue, mild flu-like symptoms
- Low. Well-established safety in clinical oncology and hepatitis trials
- More clinical data than TB-500; excellent safety record in immunocompromised populations
- Epithalon
- Telomerase activation, circadian regulation
- Insomnia, vivid dreams, mild headache
- Low. Long-term effects on cell cycling unknown
- Minimal adverse events; less mechanistic overlap with wound repair than TB-500
- Melanotan II
- Melanocortin receptor agonism, tanning, libido
- Nausea, flushing, spontaneous erections, darkening of moles
- Moderate. Cardiovascular and dermatological concerns
- Higher side effect burden and regulatory scrutiny than TB-500
- TB-500's safety profile is most comparable to BPC-157. Both are tissue-repair peptides with angiogenic properties, both lack formal phase III human trials, and both demonstrate favorable tolerability in observational research use. The key differentiator is mechanism: TB-500 works upstream at the cytoskeletal level (actin dynamics), while BPC-157 works downstream through growth factor signaling and nitric oxide pathways. This mechanistic distinction means they're often stacked in research protocols rather than compared as alternatives.